BD buys infection surveillance firm
This article was originally published in Clinica
BD Diagnostics has bolstered its portfolio of products designed to prevent and control infectious diseases by purchasing Austin, Texas-based ICPA, a specialist in infection surveillance systems. The acquisition provides BD with the AICE software system, which is designed to track and monitor emerging infection issues among patients and healthcare workers in hospitals. The software continuously tracks emerging drug-resistant organisms and the incidence of healthcare-associated infections, and generates alerts that signal critical risk of infections. BD provides a range of products for infection control, including rapid assays for detecting the presence of infectious organisms. Financial terms of the deal were not disclosed.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals